These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29726028)

  • 1. High vs low dose cyclosporine-a, after allogeneic marrow transplantation in leukemia: Long term follow up of a randomized study.
    Bacigalupo A; Van Lint MT; Sica S; Laurenti L; Rosales MB; Dominietto A; di Grazia C; Angelucci E
    Am J Hematol; 2018 May; ():. PubMed ID: 29726028
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased risk of leukemia relapse with high dose cyclosporine after allogeneic marrow transplantation for acute leukemia: 10 year follow-up of a randomized study.
    Bicigalupo A; Lamparelli T; Gualandi F; Bregante S; Raiola A; di Grazia C; Dominietto A; Romagnani C; Occhini D; Frassoni F; van Lint MT
    Blood; 2001 Nov; 98(10):3174-5. PubMed ID: 11721685
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.
    Mehta J; Powles R; Treleaven J; Horton C; Tait D; Meller S; Pinkerton CR; Middleton G; Eisen T; Singhal S
    Bone Marrow Transplant; 1996 Oct; 18(4):741-6. PubMed ID: 8899189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.
    Gordon BG; Warkentin PI; Strandjord SE; Abromowitch M; Bayever E; Harper JL; Coccia PF
    Bone Marrow Transplant; 1997 Jul; 20(1):5-10. PubMed ID: 9232249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial.
    Locatelli F; Zecca M; Rondelli R; Bonetti F; Dini G; Prete A; Messina C; Uderzo C; Ripaldi M; Porta F; Giorgiani G; Giraldi E; Pession A
    Blood; 2000 Mar; 95(5):1572-9. PubMed ID: 10688810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporine alone vs cyclosporine plus methotrexate for post-transplant immunosuppression after HLA-identical sibling bone marrow transplantation: a randomized prospective study.
    Lee KH; Choi SJ; Lee JH; Kim S; Seol M; Lee YS; Kim WK; Lee JS; Lee JH
    Bone Marrow Transplant; 2004 Oct; 34(7):627-36. PubMed ID: 15300231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low transplant mortality in allogeneic bone marrow transplantation for acute myeloid leukemia: a randomized study of low-dose cyclosporin versus low-dose cyclosporin and low-dose methotrexate.
    Zikos P; Van Lint MT; Frassoni F; Lamparelli T; Gualandi F; Occhini D; Mordini N; Berisso G; Bregante S; De Stefano F; Soracco M; Vitale V; Bacigalupo A
    Blood; 1998 May; 91(9):3503-8. PubMed ID: 9558411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts.
    Körbling M; Przepiorka D; Huh YO; Engel H; van Besien K; Giralt S; Andersson B; Kleine HD; Seong D; Deisseroth AB
    Blood; 1995 Mar; 85(6):1659-65. PubMed ID: 7888684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.
    Cassileth PA; Harrington DP; Appelbaum FR; Lazarus HM; Rowe JM; Paietta E; Willman C; Hurd DD; Bennett JM; Blume KG; Head DR; Wiernik PH
    N Engl J Med; 1998 Dec; 339(23):1649-56. PubMed ID: 9834301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
    Schwinghammer TL; Bloom EJ
    Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation.
    Fefer A; Sullivan KM; Weiden P; Buckner CD; Schoch G; Storb R; Thomas ED
    Prog Clin Biol Res; 1987; 244():401-8. PubMed ID: 3310002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment.
    Yu C; Storb R; Mathey B; Deeg HJ; Schuening FG; Graham TC; Seidel K; Burnett R; Wagner JL; Shulman H; Sandmaier BM
    Blood; 1995 Dec; 86(11):4376-81. PubMed ID: 7492799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
    Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
    Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials.
    Storb R; Deeg HJ; Fisher L; Appelbaum F; Buckner CD; Bensinger W; Clift R; Doney K; Irle C; McGuffin R
    Blood; 1988 Feb; 71(2):293-8. PubMed ID: 3276360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Low-Dose, Short-Course Mycophenolate Mofetil With Cyclosporine and Methotrexate for Graft-Versus-Host Disease Prophylaxis in Allogeneic Stem Cell Transplant.
    Ramzi M; Haghighat S; Namdari N; Haghighinejad H
    Exp Clin Transplant; 2021 Dec; 19(12):1328-1333. PubMed ID: 32778017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia.
    Kersey JH; Weisdorf D; Nesbit ME; LeBien TW; Woods WG; McGlave PB; Kim T; Vallera DA; Goldman AI; Bostrom B
    N Engl J Med; 1987 Aug; 317(8):461-7. PubMed ID: 3302708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Graft-versus-leukemia effect induced by abrupt discontinuation of cyclosporine A following allogeneic bone marrow transplantation].
    Kanamori H; Sasaki S; Ueda S; Yamazaki E; Tamura T; Harano H; Matsuzaki M; Ogawa K; Mohri H; Okubo T
    Rinsho Ketsueki; 1997 Aug; 38(8):643-6. PubMed ID: 9311269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of outcome of allogeneic bone marrow transplantation with and without granulocyte colony-stimulating factor (lenograstim) donor-marrow priming in patients with chronic myelogenous leukemia.
    Ji SQ; Chen HR; Wang HX; Yan HM; Pan SP; Xun CQ
    Biol Blood Marrow Transplant; 2002; 8(5):261-7. PubMed ID: 12064363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.
    Storb R; Deeg HJ; Whitehead J; Appelbaum F; Beatty P; Bensinger W; Buckner CD; Clift R; Doney K; Farewell V
    N Engl J Med; 1986 Mar; 314(12):729-35. PubMed ID: 3513012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission.
    Lee SH; Lee MH; Lee JH; Min YH; Lee KH; Cheong JW; Lee J; Park KW; Kang JH; Kim K; Kim WS; Jung CW; Choi SJ; Lee JH; Park K
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):122-8. PubMed ID: 15682073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.